Sunedison Inc (NYSE:SUNE), Pfizer Inc

The stock is floating in a range of $3.46 - $4.02.

Christopher Compton adds an accomplished global banking, capital markets and corporate finance;background to our board and possesses extensive financial experience from his tenure with a large public company.; Mr. Compton served in various senior finance positions with Chiquita Brand worldwide, Inc. from 1987 to 2012 after which he retired.; Following his retirement, Mr. Compton has worked as an independent consultant.

Steven Tesoriere was said to have resigned from the Board of Directors for TerraForm Power and TerraForm Global, but would remain on the SunEdison Board.

These projects will replace a portion of the projects that were part of TerraForm's initial portfolio. Some of the amount has been paid on November 20 while the rest is expected as of now, anywhere near or on December 7 in 2016.

The proceeds of the sale will help SunEdison to pay down some of its debt.

"This transaction provides higher yields replacing lower-yielding IPO projects that were meant to be attained through M&A and is consistent with our strategy to focus on organic growth offered by our sponsor", said Brian Wuebbels, Chief Executive Officer of TerraForm Global.

Up to Monday's close, SunEdison's shares had lost almost 69 per cent of their value since October 7 when the company said it would stop sales of renewable energy assets to its "yieldcos" and sell more projects to third parties.

Shares of Pfizer Inc (NYSE:PFE), gained 3.44% to $33.07. The heightened volatility saw the trading volume jump to 10,119,800 shares.

Specifically, major shareholder Montenvers Master Bluemountain bought 888,473 shares of the firm's stock in a transaction dated Tuesday, November 24th.

The study was conducted as a 15-week, double-blind, placebo-controlled, parallel group study with a primary objective to evaluate the efficacy of pregabalin in the treatment of chronic post-traumatic peripheral neuropathic pain.

Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.

Earlier this month, the company won all the 500 MW in the Andhra Pradesh online solar tender by offering a record low tariff of INR 4.63 (USD 0.070/EUR 0.066) per kWh.

Depomed declared that it will be presenting at the following investor events during the month of December.

Now what: If it sounds like SunEdison is consolidating power, that's exactly what is going on here.

This article was from Reuters and was legally licensed through the NewsCred publisher network. The Content included in this article is just for informational purposes only. Its market capitalization is $78.08 billion.